Cholesterol-lowering therapy interventions. A pharmacoeconomic assessment

M. A. Kortt, Edward P Armstrong

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Elevated cholesterol levels are associated with an increased risk of cardiovascular diseases. Treatment strategies promoting the associated health benefits from a reduction in elevated cholesterol levels have been outlined in guidelines published by the National Cholesterol Education Program. Clinicians and researchers have also examined the economic benefits associated with reducing elevated cholesterol levels. Most of these studies have employed traditional pharmacoeconomic techniques like cost-effectiveness analysis. Results from these studies indicated that certain types of therapy interventions (such as the use of cholesterol-lowering pharmaceutical agents) are cost effective. However, the majority of these studies are clinically driven and rely heavily on cost-outcome ratios as decision variables. This traditional approach to pharmacoeconomic evaluation is starting to be questioned by managed care organisations in the US. These organisations are increasingly interested in assessing the global (or health systems-based) impact associated with the introduction of a therapy intervention (such as cholesterol lowering agents). Subsequently, there is a need for pharmacoeconomic studies to provide a health systems-based view to assess a range of competing cholesterol lowering treatment options.

Original languageEnglish (US)
Pages (from-to)193-203
Number of pages11
JournalDisease Management and Health Outcomes
Volume4
Issue number4
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Pharmaceutical Economics
Hypercholesterolemia
Cholesterol
Organizations
Costs and Cost Analysis
Managed Care Programs
Insurance Benefits
Therapeutics
Cost-Benefit Analysis
Cardiovascular Diseases
Economics
Research Personnel
Guidelines
Education
Health
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Health Policy
  • Nursing(all)

Cite this

Cholesterol-lowering therapy interventions. A pharmacoeconomic assessment. / Kortt, M. A.; Armstrong, Edward P.

In: Disease Management and Health Outcomes, Vol. 4, No. 4, 1998, p. 193-203.

Research output: Contribution to journalArticle

@article{4c1e426ec87e410b9047bed0749c73ab,
title = "Cholesterol-lowering therapy interventions. A pharmacoeconomic assessment",
abstract = "Elevated cholesterol levels are associated with an increased risk of cardiovascular diseases. Treatment strategies promoting the associated health benefits from a reduction in elevated cholesterol levels have been outlined in guidelines published by the National Cholesterol Education Program. Clinicians and researchers have also examined the economic benefits associated with reducing elevated cholesterol levels. Most of these studies have employed traditional pharmacoeconomic techniques like cost-effectiveness analysis. Results from these studies indicated that certain types of therapy interventions (such as the use of cholesterol-lowering pharmaceutical agents) are cost effective. However, the majority of these studies are clinically driven and rely heavily on cost-outcome ratios as decision variables. This traditional approach to pharmacoeconomic evaluation is starting to be questioned by managed care organisations in the US. These organisations are increasingly interested in assessing the global (or health systems-based) impact associated with the introduction of a therapy intervention (such as cholesterol lowering agents). Subsequently, there is a need for pharmacoeconomic studies to provide a health systems-based view to assess a range of competing cholesterol lowering treatment options.",
author = "Kortt, {M. A.} and Armstrong, {Edward P}",
year = "1998",
doi = "10.2165/00115677-199804040-00002",
language = "English (US)",
volume = "4",
pages = "193--203",
journal = "Disease Management and Health Outcomes",
issn = "1173-8790",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Cholesterol-lowering therapy interventions. A pharmacoeconomic assessment

AU - Kortt, M. A.

AU - Armstrong, Edward P

PY - 1998

Y1 - 1998

N2 - Elevated cholesterol levels are associated with an increased risk of cardiovascular diseases. Treatment strategies promoting the associated health benefits from a reduction in elevated cholesterol levels have been outlined in guidelines published by the National Cholesterol Education Program. Clinicians and researchers have also examined the economic benefits associated with reducing elevated cholesterol levels. Most of these studies have employed traditional pharmacoeconomic techniques like cost-effectiveness analysis. Results from these studies indicated that certain types of therapy interventions (such as the use of cholesterol-lowering pharmaceutical agents) are cost effective. However, the majority of these studies are clinically driven and rely heavily on cost-outcome ratios as decision variables. This traditional approach to pharmacoeconomic evaluation is starting to be questioned by managed care organisations in the US. These organisations are increasingly interested in assessing the global (or health systems-based) impact associated with the introduction of a therapy intervention (such as cholesterol lowering agents). Subsequently, there is a need for pharmacoeconomic studies to provide a health systems-based view to assess a range of competing cholesterol lowering treatment options.

AB - Elevated cholesterol levels are associated with an increased risk of cardiovascular diseases. Treatment strategies promoting the associated health benefits from a reduction in elevated cholesterol levels have been outlined in guidelines published by the National Cholesterol Education Program. Clinicians and researchers have also examined the economic benefits associated with reducing elevated cholesterol levels. Most of these studies have employed traditional pharmacoeconomic techniques like cost-effectiveness analysis. Results from these studies indicated that certain types of therapy interventions (such as the use of cholesterol-lowering pharmaceutical agents) are cost effective. However, the majority of these studies are clinically driven and rely heavily on cost-outcome ratios as decision variables. This traditional approach to pharmacoeconomic evaluation is starting to be questioned by managed care organisations in the US. These organisations are increasingly interested in assessing the global (or health systems-based) impact associated with the introduction of a therapy intervention (such as cholesterol lowering agents). Subsequently, there is a need for pharmacoeconomic studies to provide a health systems-based view to assess a range of competing cholesterol lowering treatment options.

UR - http://www.scopus.com/inward/record.url?scp=0031736722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031736722&partnerID=8YFLogxK

U2 - 10.2165/00115677-199804040-00002

DO - 10.2165/00115677-199804040-00002

M3 - Article

VL - 4

SP - 193

EP - 203

JO - Disease Management and Health Outcomes

JF - Disease Management and Health Outcomes

SN - 1173-8790

IS - 4

ER -